# s_type = frag
# newdoc id = AMALGUM_academic_empagliflozin
# sent_id = AMALGUM_academic_empagliflozin-1
# text = 4. Discussion
1	4.	4.	X	LS	_	2	dep	2:dep	Discourse=preparation:1->2
2	Discussion	discussion	NOUN	NN	Number=Sing	0	root	0:root	Entity=(abstract-1)

# s_type = decl
# sent_id = AMALGUM_academic_empagliflozin-2
# text = iSGLT2s are a new class of oral hypoglycaemic drugs that block glucose reabsorption at the renal level , thus promoting urine glucose and sodium excretion and reducing plasma glucose levels .
1	iSGLT2s	isglt	NOUN	NNS	Number=Plur	5	nsubj	5:nsubj	Discourse=ROOT:2|Entity=(abstract-2)
2	are	be	AUX	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	5	cop	5:cop	_
3	a	a	DET	DT	Definite=Ind|PronType=Art	5	det	5:det	Entity=(abstract-2
4	new	new	ADJ	JJ	Degree=Pos	5	amod	5:amod	_
5	class	class	NOUN	NN	Number=Sing	0	root	0:root	_
6	of	of	ADP	IN	_	9	case	9:case	_
7	oral	oral	ADJ	JJ	Degree=Pos	9	amod	9:amod	Entity=(substance-3
8	hypoglycaemic	hypoglycaemic	ADJ	JJ	Degree=Pos	9	amod	9:amod	_
9	drugs	drug	NOUN	NNS	Number=Plur	5	nmod	5:nmod:of|11:nsubj	_
10	that	that	PRON	WDT	PronType=Rel	11	nsubj	9:ref	Discourse=elaboration:3->2
11	block	block	VERB	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	9	acl:relcl	9:acl:relcl	_
12	glucose	glucose	NOUN	NN	Number=Sing	13	compound	13:compound	Entity=(abstract-4(substance-5)
13	reabsorption	reabsorption	NOUN	NN	Number=Sing	11	obj	11:obj	Entity=abstract-4)
14	at	at	ADP	IN	_	17	case	17:case	_
15	the	the	DET	DT	Definite=Def|PronType=Art	17	det	17:det	Entity=(abstract-6
16	renal	renal	ADJ	JJ	Degree=Pos	17	amod	17:amod	_
17	level	level	NOUN	NN	Number=Sing	11	obl	11:obl:at	Entity=abstract-2)substance-3)abstract-6)
18	,	,	PUNCT	,	_	20	punct	20:punct	_
19	thus	thus	ADV	RB	_	20	advmod	20:advmod	Discourse=same_unit:4->2
20	promoting	promote	VERB	VBG	VerbForm=Ger	11	advcl	11:advcl	_
21	urine	urine	NOUN	NN	Number=Sing	22	compound	22:compound	Entity=(abstract-7(substance-8(substance-5(substance-9)
22	glucose	glucose	NOUN	NN	Number=Sing	25	compound	25:compound	Entity=substance-5)
23	and	and	CCONJ	CC	_	24	cc	24:cc	_
24	sodium	sodium	NOUN	NN	Number=Sing	22	conj	22:conj:and|25:compound	Entity=substance-8)(substance-10)
25	excretion	excretion	NOUN	NN	Number=Sing	20	obj	20:obj	Entity=abstract-7)
26	and	and	CCONJ	CC	_	27	cc	27:cc	Discourse=joint:5->4
27	reducing	reduce	VERB	VBG	VerbForm=Ger	20	conj	11:advcl|20:conj:and	_
28	plasma	plasma	NOUN	NN	Number=Sing	29	compound	29:compound	Entity=(abstract-11(substance-5(abstract-12)
29	glucose	glucose	NOUN	NN	Number=Sing	30	compound	30:compound	Entity=substance-5)
30	levels	level	NOUN	NNS	Number=Plur	27	obj	27:obj	Entity=abstract-11)
31	.	.	PUNCT	.	_	5	punct	5:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_empagliflozin-3
# text = In the present study , we have focused on the effects of empagliflozin on oxidative stress in the leukocytes of T2D subjects , and on inflammatory parameters .
1	In	in	ADP	IN	_	4	case	4:case	Discourse=elaboration:6->2
2	the	the	DET	DT	Definite=Def|PronType=Art	4	det	4:det	Entity=(abstract-13
3	present	present	ADJ	JJ	Degree=Pos	4	amod	4:amod	_
4	study	study	NOUN	NN	Number=Sing	8	obl	8:obl:in	Entity=abstract-13)
5	,	,	PUNCT	,	_	4	punct	4:punct	_
6	we	we	PRON	PRP	Case=Nom|Number=Plur|Person=1|PronType=Prs	8	nsubj	8:nsubj	Entity=(person-14)
7	have	have	AUX	VBP	Mood=Ind|Number=Plur|Person=1|Tense=Pres|VerbForm=Fin	8	aux	8:aux	_
8	focused	focus	VERB	VBN	Tense=Past|VerbForm=Part	0	root	0:root	_
9	on	on	ADP	IN	_	11	case	11:case	_
10	the	the	DET	DT	Definite=Def|PronType=Art	11	det	11:det	Entity=(abstract-15
11	effects	effect	NOUN	NNS	Number=Plur	8	obl	8:obl:on	_
12	of	of	ADP	IN	_	13	case	13:case	_
13	empagliflozin	empagliflozin	NOUN	NN	Number=Sing	11	nmod	11:nmod:of	Entity=(substance-16
14	on	on	ADP	IN	_	16	case	16:case	_
15	oxidative	oxidative	ADJ	JJ	Degree=Pos	16	amod	16:amod	Entity=(abstract-17
16	stress	stress	NOUN	NN	Number=Sing	13	nmod	13:nmod:on	_
17	in	in	ADP	IN	_	19	case	19:case	_
18	the	the	DET	DT	Definite=Def|PronType=Art	19	det	19:det	Entity=(abstract-18
19	leukocytes	leukocyte	NOUN	NNS	Number=Plur	16	nmod	16:nmod:in	_
20	of	of	ADP	IN	_	22	case	22:case	_
21	T2D	T2D	PROPN	NNP	Number=Sing	22	compound	22:compound	Entity=(animal-19(abstract-20)
22	subjects	subject	NOUN	NNS	Number=Plur	19	nmod	19:nmod:of	Entity=abstract-15)substance-16)abstract-17)abstract-18)animal-19)
23	,	,	PUNCT	,	_	27	punct	27:punct	_
24	and	and	CCONJ	CC	_	27	cc	27:cc	_
25	on	on	ADP	IN	_	27	case	27:case	_
26	inflammatory	inflammatory	ADJ	JJ	Degree=Pos	27	amod	27:amod	Entity=(abstract-21
27	parameters	parameter	NOUN	NNS	Number=Plur	17	conj	17:conj:and|19:case	Entity=abstract-21)
28	.	.	PUNCT	.	_	8	punct	8:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_empagliflozin-4
# text = In addition to a reduction in body weight and an improved metabolic profile — characterized by reduced plasma glucose and HbA1c levels — we observed a reduction in mitochondrial superoxide production in diabetic patients after treatment with the iSGLT2 empagliflozin , together with increased antioxidant defenses .
1	In	in	ADP	IN	_	2	case	2:case	Discourse=joint:7->6
2	addition	addition	NOUN	NN	Number=Sing	25	obl	25:obl:in	_
3	to	to	ADP	IN	_	5	case	5:case	_
4	a	a	DET	DT	Definite=Ind|PronType=Art	5	det	5:det	Entity=(abstract-22
5	reduction	reduction	NOUN	NN	Number=Sing	2	nmod	2:nmod:to	_
6	in	in	ADP	IN	_	8	case	8:case	_
7	body	body	NOUN	NN	Number=Sing	8	compound	8:compound	Entity=(abstract-23(object-24)
8	weight	weight	NOUN	NN	Number=Sing	5	nmod	5:nmod:in	Entity=abstract-22)abstract-23)
9	and	and	CCONJ	CC	_	13	cc	13:cc	_
10	an	a	DET	DT	Definite=Ind|PronType=Art	13	det	13:det	Entity=(abstract-25
11	improved	improve	VERB	VBN	Tense=Past|VerbForm=Part	13	amod	13:amod	_
12	metabolic	metabolic	ADJ	JJ	Degree=Pos	13	amod	13:amod	_
13	profile	profile	NOUN	NN	Number=Sing	5	conj	2:nmod:to|5:conj:and	_
14	—	—	PUNCT	:	_	15	punct	15:punct	Discourse=elaboration:8->7
15	characterized	characterize	VERB	VBN	Tense=Past|VerbForm=Part	13	acl	13:acl	_
16	by	by	ADP	IN	_	22	case	22:case	_
17	reduced	reduce	VERB	VBN	Tense=Past|VerbForm=Part	19	amod	19:amod	Entity=(abstract-11(substance-8(substance-5
18	plasma	plasma	NOUN	NN	Number=Sing	19	compound	19:compound	Entity=(abstract-12)
19	glucose	glucose	NOUN	NN	Number=Sing	22	compound	22:compound	Entity=substance-5)
20	and	and	CCONJ	CC	_	21	cc	21:cc	_
21	HbA1c	HbA1c	NOUN	NN	Number=Sing	19	conj	19:conj:and|22:compound	Entity=substance-8)(abstract-26)
22	levels	level	NOUN	NNS	Number=Plur	15	obl	15:obl:by	Entity=abstract-25)abstract-11)
23	—	—	PUNCT	:	_	2	punct	2:punct	_
24	we	we	PRON	PRP	Case=Nom|Number=Plur|Person=1|PronType=Prs	25	nsubj	25:nsubj	Discourse=elaboration:9->8|Entity=(person-14)
25	observed	observe	VERB	VBD	Mood=Ind|Number=Plur|Person=1|Tense=Past|VerbForm=Fin	0	root	0:root	_
26	a	a	DET	DT	Definite=Ind|PronType=Art	27	det	27:det	Entity=(abstract-22
27	reduction	reduction	NOUN	NN	Number=Sing	25	obj	25:obj	_
28	in	in	ADP	IN	_	31	case	31:case	_
29	mitochondrial	mitochondrial	ADJ	JJ	Degree=Pos	31	amod	31:amod	Entity=(abstract-27
30	superoxide	superoxide	NOUN	NN	Number=Sing	31	compound	31:compound	Entity=(substance-28)
31	production	production	NOUN	NN	Number=Sing	27	nmod	27:nmod:in	_
32	in	in	ADP	IN	_	34	case	34:case	_
33	diabetic	diabetic	ADJ	JJ	Degree=Pos	34	amod	34:amod	Entity=(person-29
34	patients	patient	NOUN	NNS	Number=Plur	31	nmod	31:nmod:in	Entity=abstract-22)abstract-27)person-29)
35	after	after	ADP	IN	_	36	case	36:case	_
36	treatment	treatment	NOUN	NN	Number=Sing	25	obl	25:obl:after	Entity=(abstract-30
37	with	with	ADP	IN	_	40	case	40:case	_
38	the	the	DET	DT	Definite=Def|PronType=Art	40	det	40:det	Entity=(substance-16
39	iSGLT2	iSGLT2	PROPN	NNP	Number=Sing	40	compound	40:compound	Entity=(abstract-31)
40	empagliflozin	empagliflozin	NOUN	NN	Number=Sing	36	nmod	36:nmod:with	Entity=abstract-30)substance-16)
41	,	,	PUNCT	,	_	46	punct	46:punct	_
42	together	together	ADV	RB	Degree=Pos	46	advmod	46:advmod	Entity=(abstract-32
43	with	with	ADP	IN	_	46	case	46:case	_
44	increased	increase	VERB	VBN	Tense=Past|VerbForm=Part	46	amod	46:amod	_
45	antioxidant	antioxidant	ADJ	JJ	Degree=Pos	46	amod	46:amod	_
46	defenses	defense	NOUN	NNS	Number=Plur	25	obl	25:obl:with	Entity=abstract-32)
47	.	.	PUNCT	.	_	25	punct	25:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_empagliflozin-5
# text = Moreover , reduced proinflammatory markers and increased anti-inflammatory parameters were maintained after 24 weeks of treatment with empagliflozin .
1	Moreover	moreover	ADV	RB	Degree=Pos	11	advmod	11:advmod	Discourse=joint:10->7
2	,	,	PUNCT	,	_	1	punct	1:punct	_
3	reduced	reduce	VERB	VBN	Tense=Past|VerbForm=Part	5	amod	5:amod	Entity=(abstract-33
4	proinflammatory	proinflammatory	ADJ	JJ	Degree=Pos	5	amod	5:amod	_
5	markers	marker	NOUN	NNS	Number=Plur	11	nsubj:pass	11:nsubj:pass	Entity=abstract-33)
6	and	and	CCONJ	CC	_	9	cc	9:cc	_
7	increased	increase	VERB	VBD	Mood=Ind|Number=Sing|Person=3|Tense=Past|VerbForm=Fin	9	amod	9:amod	Entity=(abstract-21
8	anti-inflammatory	anti-inflammatory	ADJ	JJ	Degree=Pos	9	amod	9:amod	_
9	parameters	parameter	NOUN	NNS	Number=Plur	5	conj	5:conj:and|11:nsubj:pass	Entity=abstract-21)
10	were	be	AUX	VBD	Mood=Ind|Number=Plur|Person=3|Tense=Past|VerbForm=Fin	11	aux:pass	11:aux:pass	_
11	maintained	maintain	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
12	after	after	ADP	IN	_	14	case	14:case	_
13	24	24	NUM	CD	NumForm=Digit|NumType=Card	14	nummod	14:nummod	Entity=(time-34
14	weeks	week	NOUN	NNS	Number=Plur	11	obl	11:obl:after	_
15	of	of	ADP	IN	_	16	case	16:case	_
16	treatment	treatment	NOUN	NN	Number=Sing	14	nmod	14:nmod:of	Entity=(abstract-30
17	with	with	ADP	IN	_	18	case	18:case	_
18	empagliflozin	empagliflozin	NOUN	NN	Number=Sing	16	nmod	16:nmod:with	Entity=time-34)abstract-30)(substance-16)
19	.	.	PUNCT	.	_	11	punct	11:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_empagliflozin-6
# text = Besides their glucose-lowering effect , iSGLT2s produce changes in the lipid profile that should also be highlighted .
1	Besides	besides	ADP	IN	_	4	case	4:case	Discourse=elaboration:11->10
2	their	their	PRON	PRP$	Number=Plur|Person=3|Poss=Yes|PronType=Prs	4	nmod:poss	4:nmod:poss	Entity=(abstract-35(abstract-21)
3	glucose-lowering	glucose-lowering	NOUN	NN	Number=Sing	4	compound	4:compound	Entity=(substance-36)
4	effect	effect	NOUN	NN	Number=Sing	7	obl	7:obl:besides	Entity=abstract-35)
5	,	,	PUNCT	,	_	4	punct	4:punct	_
6	iSGLT2s	isglt	NOUN	NNS	Number=Plur	7	nsubj	7:nsubj	Discourse=elaboration:12->11|Entity=(abstract-2)
7	produce	produce	VERB	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	0	root	0:root	_
8	changes	change	NOUN	NNS	Number=Plur	7	obj	7:obj|17:nsubj:pass	Entity=(abstract-37
9	in	in	ADP	IN	_	12	case	12:case	_
10	the	the	DET	DT	Definite=Def|PronType=Art	12	det	12:det	Entity=(abstract-25
11	lipid	lipid	NOUN	NN	Number=Sing	12	compound	12:compound	Entity=(substance-38)
12	profile	profile	NOUN	NN	Number=Sing	8	nmod	8:nmod:in	Entity=abstract-25)
13	that	that	PRON	WDT	PronType=Rel	17	nsubj:pass	8:ref	Discourse=elaboration:13->12
14	should	should	AUX	MD	VerbForm=Fin	17	aux	17:aux	_
15	also	also	ADV	RB	_	17	advmod	17:advmod	_
16	be	be	AUX	VB	VerbForm=Inf	17	aux:pass	17:aux:pass	_
17	highlighted	highlight	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	8	acl:relcl	8:acl:relcl	Entity=abstract-37)
18	.	.	PUNCT	.	_	7	punct	7:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_empagliflozin-7
# text = Empagliflozin treatment is correlated with increased total cholesterol due to slight increases in HDL-c and LDL-c , as we have observed , and reported in other studies .
1	Empagliflozin	Empagliflozin	PROPN	NNP	Number=Sing	2	compound	2:compound	Discourse=joint:14->10|Entity=(abstract-30(substance-16)
2	treatment	treatment	NOUN	NN	Number=Sing	4	nsubj:pass	4:nsubj:pass	Entity=abstract-30)
3	is	be	AUX	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	4	aux:pass	4:aux:pass	_
4	correlated	correlate	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
5	with	with	ADP	IN	_	8	case	8:case	_
6	increased	increase	VERB	VBN	Tense=Past|VerbForm=Part	8	amod	8:amod	Entity=(substance-39
7	total	total	ADJ	JJ	Degree=Pos	8	amod	8:amod	_
8	cholesterol	cholesterol	NOUN	NN	Number=Sing	4	obl	4:obl:with	_
9	due	due	ADJ	JJ	Degree=Pos	8	acl	8:acl	Discourse=cause:15->14
10	to	to	ADP	IN	_	12	case	12:case	_
11	slight	slight	ADJ	JJ	Degree=Pos	12	amod	12:amod	Entity=(event-40
12	increases	increase	NOUN	NNS	Number=Plur	9	obl	9:obl:to	_
13	in	in	ADP	IN	_	14	case	14:case	_
14	HDL-c	HDL-c	PROPN	NNP	Number=Sing	12	nmod	12:nmod:in	Entity=(abstract-41)
15	and	and	CCONJ	CC	_	16	cc	16:cc	_
16	LDL-c	LDL-c	PROPN	NNP	Number=Sing	14	conj	12:nmod:in|14:conj:and	Entity=substance-39)event-40)(abstract-42)
17	,	,	PUNCT	,	_	21	punct	21:punct	_
18	as	as	SCONJ	IN	_	21	mark	21:mark	Discourse=manner:16->15
19	we	we	PRON	PRP	Case=Nom|Number=Plur|Person=1|PronType=Prs	21	nsubj	21:nsubj|24:nsubj	Entity=(person-14)
20	have	have	AUX	VBP	Mood=Ind|Number=Plur|Person=1|Tense=Pres|VerbForm=Fin	21	aux	21:aux|24:aux	_
21	observed	observe	VERB	VBN	Tense=Past|VerbForm=Part	9	advcl	9:advcl:as	_
22	,	,	PUNCT	,	_	24	punct	24:punct	_
23	and	and	CCONJ	CC	_	24	cc	24:cc	Discourse=joint:17->16
24	reported	report	VERB	VBN	Tense=Past|VerbForm=Part	21	conj	9:advcl:as|21:conj:and	_
25	in	in	ADP	IN	_	27	case	27:case	_
26	other	other	ADJ	JJ	Degree=Pos	27	amod	27:amod	Entity=(abstract-43
27	studies	study	NOUN	NNS	Number=Plur	24	obl	24:obl:in	Entity=abstract-43)
28	.	.	PUNCT	.	_	4	punct	4:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_empagliflozin-8
# text = However , there is a well-documented cardiovascular protection exerted by iSGLT2s , which endows these drugs with clinical potential .
1	However	however	ADV	RB	_	4	advmod	4:advmod	Discourse=contrast:18->14
2	,	,	PUNCT	,	_	1	punct	1:punct	_
3	there	there	PRON	EX	_	4	expl	4:expl	_
4	is	be	VERB	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	0	root	0:root	_
5	a	a	DET	DT	Definite=Ind|PronType=Art	8	det	8:det	Entity=(abstract-44
6	well-documented	well-documented	ADJ	JJ	Degree=Pos	8	amod	8:amod	_
7	cardiovascular	cardiovascular	ADJ	JJ	Degree=Pos	8	amod	8:amod	_
8	protection	protection	NOUN	NN	Number=Sing	4	nsubj	4:nsubj|14:nsubj	_
9	exerted	exert	VERB	VBN	Tense=Past|VerbForm=Part	8	acl	8:acl	Discourse=elaboration:19->18
10	by	by	ADP	IN	_	11	case	11:case	_
11	iSGLT2s	iSGLTl	PROPN	NNPS	Number=Plur	9	obl	9:obl:by	Entity=(abstract-2)
12	,	,	PUNCT	,	_	14	punct	14:punct	_
13	which	which	PRON	WDT	PronType=Rel	14	nsubj	8:ref	Discourse=elaboration:20->18
14	endows	endow	VERB	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	8	acl:relcl	8:acl:relcl	_
15	these	this	DET	DT	Number=Plur|PronType=Dem	16	det	16:det	Entity=(substance-3
16	drugs	drug	NOUN	NNS	Number=Plur	14	obj	14:obj	Entity=substance-3)
17	with	with	ADP	IN	_	19	case	19:case	_
18	clinical	clinical	ADJ	JJ	Degree=Pos	19	amod	19:amod	Entity=(abstract-45
19	potential	potential	NOUN	NN	Number=Sing	14	obl	14:obl:with	Entity=abstract-44)abstract-45)
20	.	.	PUNCT	.	_	4	punct	4:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_empagliflozin-9
# text = This has been reflected by several studies , such as the EMPA-REG OUTCOME study in which a reduction of 38 % in cardiovascular mortality was evident in the empagliflozin vs. placebo group .
1	This	this	PRON	DT	Number=Sing|PronType=Dem	4	nsubj:pass	4:nsubj:pass	Discourse=concession:21->23|Entity=(abstract-45)
2	has	have	AUX	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	4	aux	4:aux	_
3	been	be	AUX	VBN	Tense=Past|VerbForm=Part	4	aux:pass	4:aux:pass	_
4	reflected	reflect	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
5	by	by	ADP	IN	_	7	case	7:case	_
6	several	several	ADJ	JJ	Degree=Pos	7	amod	7:amod	Entity=(abstract-43
7	studies	study	NOUN	NNS	Number=Plur	4	obl	4:obl:by	_
8	,	,	PUNCT	,	_	14	punct	14:punct	_
9	such	such	ADJ	JJ	Degree=Pos	14	case	14:case	_
10	as	as	ADP	IN	_	9	fixed	9:fixed	_
11	the	the	DET	DT	Definite=Def|PronType=Art	14	det	14:det	Entity=(abstract-13
12	EMPA-REG	Empa-reg	PROPN	NNP	Number=Sing	14	compound	14:compound	Entity=(abstract-46)
13	OUTCOME	OUTCOME	PROPN	NNP	Number=Sing	14	compound	14:compound	Entity=(abstract-47)
14	study	study	NOUN	NN	Number=Sing	7	nmod	7:nmod:such_as|26:obl:in	_
15	in	in	ADP	IN	_	16	case	16:case	Discourse=elaboration:22->21
16	which	which	PRON	WDT	PronType=Rel	26	obl	14:ref	_
17	a	a	DET	DT	Definite=Ind|PronType=Art	18	det	18:det	Entity=(abstract-22
18	reduction	reduction	NOUN	NN	Number=Sing	26	nsubj	26:nsubj	_
19	of	of	ADP	IN	_	21	case	21:case	_
20	38	38	NUM	CD	NumForm=Digit|NumType=Card	21	nummod	21:nummod	Entity=(abstract-48
21	%	%	SYM	NN	Number=Sing	18	nmod	18:nmod:of	_
22	in	in	ADP	IN	_	24	case	24:case	_
23	cardiovascular	cardiovascular	ADJ	JJ	Degree=Pos	24	amod	24:amod	Entity=(abstract-49
24	mortality	mortality	NOUN	NN	Number=Sing	21	nmod	21:nmod:in	Entity=abstract-22)abstract-48)abstract-49)
25	was	be	AUX	VBD	Mood=Ind|Number=Sing|Person=3|Tense=Past|VerbForm=Fin	26	cop	26:cop	_
26	evident	evident	ADJ	JJ	Degree=Pos	14	acl:relcl	14:acl:relcl	_
27	in	in	ADP	IN	_	32	case	32:case	_
28	the	the	DET	DT	Definite=Def|PronType=Art	32	det	32:det	Entity=(animal-50
29	empagliflozin	empagliflozin	NOUN	NN	Number=Sing	32	compound	32:compound	Entity=(substance-16)
30	vs.	versus	ADP	IN	Abbr=Yes	31	cc	31:cc	_
31	placebo	placebo	NOUN	NN	Number=Sing	29	conj	29:conj:versus|32:compound	Entity=(substance-51)
32	group	group	NOUN	NN	Number=Sing	26	obl	26:obl:in	Entity=abstract-43)abstract-13)animal-50)
33	.	.	PUNCT	.	_	4	punct	4:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_empagliflozin-10
# text = However , neither the reduction in HbA1c observed in the study ( 0.60 % over 12 weeks ) nor the reduction in SBP ( up to 5 mmHg ) are sufficient to explain the reported protection against cardiovascular mortality .
1	However	however	ADV	RB	_	31	advmod	31:advmod	Discourse=joint:23->18
2	,	,	PUNCT	,	_	1	punct	1:punct	_
3	neither	neither	CCONJ	CC	_	5	advmod	5:advmod	Entity=(abstract-22
4	the	the	DET	DT	Definite=Def|PronType=Art	5	det	5:det	_
5	reduction	reduction	NOUN	NN	Number=Sing	31	nsubj	31:nsubj	_
6	in	in	ADP	IN	_	7	case	7:case	_
7	HbA1c	HbA1c	PROPN	NNP	Number=Sing	5	nmod	5:nmod:in	Entity=(abstract-26)
8	observed	observe	VERB	VBD	Mood=Ind|Number=Sing|Person=3|Tense=Past|VerbForm=Fin	5	acl	5:acl	Discourse=elaboration:24->23
9	in	in	ADP	IN	_	11	case	11:case	_
10	the	the	DET	DT	Definite=Def|PronType=Art	11	det	11:det	Entity=(abstract-13
11	study	study	NOUN	NN	Number=Sing	8	obl	8:obl:in	Entity=abstract-22)abstract-13)
12	(	(	PUNCT	-LRB-	_	14	punct	14:punct	Discourse=restatement:25->24
13	0.60	0.60	NUM	CD	NumForm=Digit|NumType=Card	14	nummod	14:nummod	Entity=(abstract-22
14	%	%	SYM	NN	Number=Sing	5	appos	5:appos	_
15	over	over	ADP	IN	_	17	case	17:case	_
16	12	12	NUM	CD	NumForm=Digit|NumType=Card	17	nummod	17:nummod	Entity=(time-52
17	weeks	week	NOUN	NNS	Number=Plur	14	nmod	14:nmod:over	Entity=abstract-22)time-52)
18	)	)	PUNCT	-RRB-	_	14	punct	14:punct	_
19	nor	nor	CCONJ	CC	_	21	cc	21:cc	Discourse=same_unit:26->24
20	the	the	DET	DT	Definite=Def|PronType=Art	21	det	21:det	Entity=(abstract-22
21	reduction	reduction	NOUN	NN	Number=Sing	5	conj	5:conj:nor|31:nsubj	_
22	in	in	ADP	IN	_	23	case	23:case	_
23	SBP	SBP	PROPN	NNP	Number=Sing	21	nmod	21:nmod:in	Entity=abstract-22)(abstract-53)
24	(	(	PUNCT	-LRB-	_	28	punct	28:punct	Discourse=elaboration:27->26
25	up	up	ADV	RB	Degree=Pos	28	advmod	28:advmod	Entity=(abstract-22
26	to	to	ADP	IN	_	25	fixed	25:fixed	_
27	5	5	NUM	CD	NumForm=Digit|NumType=Card	28	nummod	28:nummod	_
28	mmHg	mmHg	NOUN	NN	Number=Sing	21	appos	21:appos	Entity=abstract-22)
29	)	)	PUNCT	-RRB-	_	28	punct	28:punct	_
30	are	be	AUX	VBP	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	31	cop	31:cop	Discourse=same_unit:28->23
31	sufficient	sufficient	ADJ	JJ	Degree=Pos	0	root	0:root	_
32	to	to	PART	TO	_	33	mark	33:mark	Discourse=purpose:29->28
33	explain	explain	VERB	VB	VerbForm=Inf	31	csubj	31:csubj	_
34	the	the	DET	DT	Definite=Def|PronType=Art	36	det	36:det	Entity=(abstract-44
35	reported	report	VERB	VBN	Tense=Past|VerbForm=Part	36	amod	36:amod	_
36	protection	protection	NOUN	NN	Number=Sing	33	obj	33:obj	_
37	against	against	ADP	IN	_	39	case	39:case	_
38	cardiovascular	cardiovascular	ADJ	JJ	Degree=Pos	39	amod	39:amod	Entity=(abstract-49
39	mortality	mortality	NOUN	NN	Number=Sing	36	nmod	36:nmod:against	Entity=abstract-44)abstract-49)
40	.	.	PUNCT	.	_	31	punct	31:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_empagliflozin-11
# text = Interestingly , as little as 24 weeks of treatment with iSGLT2 is sufficient to witness their beneficial effects on HbA1c , body weight , blood pressure and , most importantly , on the cardiovascular system .
1	Interestingly	interestingly	ADV	RB	Degree=Pos	13	advmod	13:advmod	Discourse=joint:30->23
2	,	,	PUNCT	,	_	1	punct	1:punct	_
3	as	as	ADV	RB	_	4	advmod	4:advmod	Entity=(time-54
4	little	little	ADV	RB	Degree=Pos	6	advmod	6:advmod	_
5	as	as	ADP	IN	_	4	fixed	4:fixed	_
6	24	24	NUM	CD	NumForm=Digit|NumType=Card	7	nummod	7:nummod	_
7	weeks	week	NOUN	NNS	Number=Plur	13	nsubj	13:nsubj|15:nsubj:xsubj	_
8	of	of	ADP	IN	_	9	case	9:case	_
9	treatment	treatment	NOUN	NN	Number=Sing	7	nmod	7:nmod:of	Entity=(abstract-30
10	with	with	ADP	IN	_	11	case	11:case	_
11	iSGLT2	iSGLT2	PROPN	NNP	Number=Sing	9	nmod	9:nmod:with	Entity=time-54)abstract-30)(abstract-31)
12	is	be	AUX	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	13	cop	13:cop	_
13	sufficient	sufficient	ADJ	JJ	Degree=Pos	0	root	0:root	_
14	to	to	PART	TO	_	15	mark	15:mark	Discourse=elaboration:31->30
15	witness	witness	VERB	VB	VerbForm=Inf	13	xcomp	13:xcomp	_
16	their	their	PRON	PRP$	Number=Plur|Person=3|Poss=Yes|PronType=Prs	18	nmod:poss	18:nmod:poss	Entity=(abstract-15(time-54)
17	beneficial	beneficial	ADJ	JJ	Degree=Pos	18	amod	18:amod	_
18	effects	effect	NOUN	NNS	Number=Plur	15	obj	15:obj	_
19	on	on	ADP	IN	_	20	case	20:case	_
20	HbA1c	HbA1c	NOUN	NN	Number=Sing	18	nmod	18:nmod:on	Entity=(abstract-26)
21	,	,	PUNCT	,	_	23	punct	23:punct	_
22	body	body	NOUN	NN	Number=Sing	23	compound	23:compound	Entity=(abstract-23(object-24)
23	weight	weight	NOUN	NN	Number=Sing	20	conj	18:nmod:on|20:conj	Entity=abstract-23)
24	,	,	PUNCT	,	_	26	punct	26:punct	_
25	blood	blood	NOUN	NN	Number=Sing	26	compound	26:compound	Entity=(abstract-55
26	pressure	pressure	NOUN	NN	Number=Sing	20	conj	18:nmod:on|20:conj	Entity=abstract-15)abstract-55)
27	and	and	CCONJ	CC	_	35	cc	35:cc	_
28	,	,	PUNCT	,	_	27	punct	27:punct	_
29	most	most	ADV	RBS	Degree=Sup	30	advmod	30:advmod	Entity=(abstract-56
30	importantly	importantly	ADV	RB	Degree=Pos	35	advmod	35:advmod	_
31	,	,	PUNCT	,	_	30	punct	30:punct	_
32	on	on	ADP	IN	_	35	case	35:case	_
33	the	the	DET	DT	Definite=Def|PronType=Art	35	det	35:det	_
34	cardiovascular	cardiovascular	ADJ	JJ	Degree=Pos	35	amod	35:amod	_
35	system	system	NOUN	NN	Number=Sing	19	conj	19:conj:and|20:case	Entity=abstract-56)
36	.	.	PUNCT	.	_	13	punct	13:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_empagliflozin-12
# text = As an example , the reduction in hospitalization rates for heart failure in the group treated with empagliflozin in the EMPA-REG OUTCOME study was already significant at this time point .
1	As	as	ADP	IN	_	3	case	3:case	Discourse=joint:32->30
2	an	a	DET	DT	Definite=Ind|PronType=Art	3	det	3:det	Entity=(abstract-57
3	example	example	NOUN	NN	Number=Sing	26	obl	26:obl:as	Entity=abstract-57)
4	,	,	PUNCT	,	_	3	punct	3:punct	_
5	the	the	DET	DT	Definite=Def|PronType=Art	6	det	6:det	Entity=(abstract-22
6	reduction	reduction	NOUN	NN	Number=Sing	26	nsubj	26:nsubj	_
7	in	in	ADP	IN	_	9	case	9:case	_
8	hospitalization	hospitalization	NOUN	NN	Number=Sing	9	compound	9:compound	Entity=(abstract-58(abstract-59)
9	rates	rate	NOUN	NNS	Number=Plur	6	nmod	6:nmod:in	_
10	for	for	ADP	IN	_	12	case	12:case	_
11	heart	heart	NOUN	NN	Number=Sing	12	compound	12:compound	Entity=(event-60(object-61)
12	failure	failure	NOUN	NN	Number=Sing	9	nmod	9:nmod:for	Entity=event-60)
13	in	in	ADP	IN	_	15	case	15:case	_
14	the	the	DET	DT	Definite=Def|PronType=Art	15	det	15:det	Entity=(animal-50
15	group	group	NOUN	NN	Number=Sing	9	nmod	9:nmod:in	_
16	treated	treat	VERB	VBN	Tense=Past|VerbForm=Part	15	acl	15:acl	Discourse=elaboration:33->32
17	with	with	ADP	IN	_	18	case	18:case	_
18	empagliflozin	empagliflozin	NOUN	NN	Number=Sing	16	obl	16:obl:with	Entity=(substance-16)
19	in	in	ADP	IN	_	23	case	23:case	_
20	the	the	DET	DT	Definite=Def|PronType=Art	23	det	23:det	Entity=(abstract-13
21	EMPA-REG	Empa-reg	PROPN	NNP	Number=Sing	23	compound	23:compound	Entity=(abstract-46)
22	OUTCOME	OUTCOME	PROPN	NNP	Number=Sing	23	compound	23:compound	Entity=(abstract-47)
23	study	study	NOUN	NN	Number=Sing	16	obl	16:obl:in	Entity=abstract-22)abstract-58)animal-50)abstract-13)
24	was	be	AUX	VBD	Mood=Ind|Number=Sing|Person=3|Tense=Past|VerbForm=Fin	26	cop	26:cop	Discourse=same_unit:34->32
25	already	already	ADV	RB	_	26	advmod	26:advmod	_
26	significant	significant	ADJ	JJ	Degree=Pos	0	root	0:root	_
27	at	at	ADP	IN	_	30	case	30:case	_
28	this	this	DET	DT	Number=Sing|PronType=Dem	30	det	30:det	Entity=(time-62
29	time	time	NOUN	NN	Number=Sing	30	compound	30:compound	_
30	point	point	NOUN	NN	Number=Sing	26	obl	26:obl:at	Entity=time-62)
31	.	.	PUNCT	.	_	26	punct	26:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_empagliflozin-13
# text = A recent study demonstrated an improved arterial stiffness after 6 weeks of treatment with empagliflozin in T2D patients , and hs-CRP was shown to be one of the main significant determinants for this improvement .
1	A	a	DET	DT	Definite=Ind|PronType=Art	3	det	3:det	Discourse=joint:35->32|Entity=(abstract-13
2	recent	recent	ADJ	JJ	Degree=Pos	3	amod	3:amod	_
3	study	study	NOUN	NN	Number=Sing	4	nsubj	4:nsubj	Entity=abstract-13)
4	demonstrated	demonstrate	VERB	VBD	Mood=Ind|Number=Sing|Person=3|Tense=Past|VerbForm=Fin	0	root	0:root	_
5	an	a	DET	DT	Definite=Ind|PronType=Art	8	det	8:det	Entity=(abstract-63
6	improved	improve	VERB	VBN	Tense=Past|VerbForm=Part	8	amod	8:amod	_
7	arterial	arterial	ADJ	JJ	Degree=Pos	8	amod	8:amod	_
8	stiffness	stiffness	NOUN	NN	Number=Sing	4	obj	4:obj	Entity=abstract-63)
9	after	after	ADP	IN	_	11	case	11:case	_
10	6	6	NUM	CD	NumForm=Digit|NumType=Card	11	nummod	11:nummod	Entity=(time-64
11	weeks	week	NOUN	NNS	Number=Plur	4	obl	4:obl:after	_
12	of	of	ADP	IN	_	13	case	13:case	_
13	treatment	treatment	NOUN	NN	Number=Sing	11	nmod	11:nmod:of	Entity=(abstract-30
14	with	with	ADP	IN	_	15	case	15:case	_
15	empagliflozin	empagliflozin	NOUN	NN	Number=Sing	13	nmod	13:nmod:with	Entity=(substance-16
16	in	in	ADP	IN	_	18	case	18:case	_
17	T2D	T2D	NOUN	NN	Number=Sing	18	compound	18:compound	Entity=(person-29(abstract-20)
18	patients	patient	NOUN	NNS	Number=Plur	15	nmod	15:nmod:in	Entity=time-64)abstract-30)substance-16)person-29)
19	,	,	PUNCT	,	_	23	punct	23:punct	_
20	and	and	CCONJ	CC	_	23	cc	23:cc	Discourse=joint:36->35
21	hs-CRP	hs-CRP	PROPN	NNP	Number=Sing	23	nsubj:pass	23:nsubj:pass|26:nsubj:xsubj	Entity=(abstract-65)
22	was	be	AUX	VBD	Mood=Ind|Number=Sing|Person=3|Tense=Past|VerbForm=Fin	23	aux:pass	23:aux:pass	_
23	shown	show	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	4	conj	4:conj:and	_
24	to	to	PART	TO	_	26	mark	26:mark	_
25	be	be	AUX	VB	VerbForm=Inf	26	cop	26:cop	_
26	one	one	NUM	CD	NumForm=Word|NumType=Card	23	xcomp	23:xcomp	Entity=(abstract-66
27	of	of	ADP	IN	_	31	case	31:case	_
28	the	the	DET	DT	Definite=Def|PronType=Art	31	det	31:det	Entity=(abstract-67
29	main	main	ADJ	JJ	Degree=Pos	31	amod	31:amod	_
30	significant	significant	ADJ	JJ	Degree=Pos	31	amod	31:amod	_
31	determinants	determinant	NOUN	NNS	Number=Plur	26	nmod	26:nmod:of	_
32	for	for	ADP	IN	_	34	case	34:case	_
33	this	this	DET	DT	Number=Sing|PronType=Dem	34	det	34:det	Entity=(event-68
34	improvement	improvement	NOUN	NN	Number=Sing	31	nmod	31:nmod:for	Entity=abstract-66)abstract-67)event-68)
35	.	.	PUNCT	.	_	4	punct	4:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_empagliflozin-14
# text = Nevertheless , despite the available evidence , the molecular mechanisms underlying the cardiovascular protection attributable to iSGLT2 treatment are still unknown , though amelioration of oxidative stress has been hypothesized to be a potential contributor .
1	Nevertheless	nevertheless	ADV	RB	Degree=Pos	21	advmod	21:advmod	Discourse=concession:37->35
2	,	,	PUNCT	,	_	1	punct	1:punct	_
3	despite	despite	ADP	IN	_	6	case	6:case	_
4	the	the	DET	DT	Definite=Def|PronType=Art	6	det	6:det	Entity=(abstract-69
5	available	available	ADJ	JJ	Degree=Pos	6	amod	6:amod	_
6	evidence	evidence	NOUN	NN	Number=Sing	21	obl	21:obl:despite	Entity=abstract-69)
7	,	,	PUNCT	,	_	6	punct	6:punct	_
8	the	the	DET	DT	Definite=Def|PronType=Art	10	det	10:det	Discourse=same_unit:38->37|Entity=(abstract-70
9	molecular	molecular	ADJ	JJ	Degree=Pos	10	amod	10:amod	_
10	mechanisms	mechanism	NOUN	NNS	Number=Plur	21	nsubj	21:nsubj	_
11	underlying	underlie	VERB	VBG	VerbForm=Ger	10	acl	10:acl	Discourse=elaboration:39->38
12	the	the	DET	DT	Definite=Def|PronType=Art	14	det	14:det	Entity=(abstract-44
13	cardiovascular	cardiovascular	ADJ	JJ	Degree=Pos	14	amod	14:amod	_
14	protection	protection	NOUN	NN	Number=Sing	11	obj	11:obj	_
15	attributable	attributable	ADJ	JJ	Degree=Pos	14	acl	14:acl	Discourse=elaboration:40->39
16	to	to	ADP	IN	_	18	case	18:case	_
17	iSGLT2	iSGLT2	PROPN	NNP	Number=Sing	18	compound	18:compound	Entity=(abstract-30(abstract-31)
18	treatment	treatment	NOUN	NN	Number=Sing	15	obl	15:obl:to	Entity=abstract-70)abstract-44)abstract-30)
19	are	be	AUX	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	21	cop	21:cop	_
20	still	still	ADV	RB	Degree=Pos	21	advmod	21:advmod	_
21	unknown	unknown	ADJ	JJ	Degree=Pos|Polarity=Neg	0	root	0:root	_
22	,	,	PUNCT	,	_	30	punct	30:punct	_
23	though	though	SCONJ	IN	_	30	mark	30:mark	Discourse=concession:41->38
24	amelioration	amelioration	NOUN	NN	Number=Sing	30	nsubj:pass	30:nsubj:pass|35:nsubj:xsubj	Entity=(abstract-71
25	of	of	ADP	IN	_	27	case	27:case	_
26	oxidative	oxidative	NOUN	NN	Number=Sing	27	compound	27:compound	Entity=(abstract-17(abstract-72)
27	stress	stress	NOUN	NN	Number=Sing	24	nmod	24:nmod:of	Entity=abstract-71)abstract-17)
28	has	have	AUX	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	30	aux	30:aux	_
29	been	be	AUX	VBN	Tense=Past|VerbForm=Part	30	aux:pass	30:aux:pass	_
30	hypothesized	hypothesize	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	21	advcl	21:advcl:though	_
31	to	to	PART	TO	_	35	mark	35:mark	_
32	be	be	AUX	VB	VerbForm=Inf	35	cop	35:cop	_
33	a	a	DET	DT	Definite=Ind|PronType=Art	35	det	35:det	Entity=(abstract-73
34	potential	potential	ADJ	JJ	Degree=Pos	35	amod	35:amod	_
35	contributor	contributor	NOUN	NN	Number=Sing	30	xcomp	30:xcomp	Entity=abstract-73)
36	.	.	PUNCT	.	_	21	punct	21:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_empagliflozin-15
# text = Because cardiac tissue possesses low antioxidant defenses , increasing the expression or activity of antioxidant enzymes could be a mechanism of cardiac protection under high risk situations such as T2D .
1	Because	because	SCONJ	IN	_	4	mark	4:mark	Discourse=joint:42->35
2	cardiac	cardiac	ADJ	JJ	Degree=Pos	3	amod	3:amod	Entity=(object-74
3	tissue	tissue	NOUN	NN	Number=Sing	4	nsubj	4:nsubj	Entity=object-74)
4	possesses	possess	VERB	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	20	advcl	20:advcl:because	_
5	low	low	ADJ	JJ	Degree=Pos	7	amod	7:amod	Entity=(abstract-32
6	antioxidant	antioxidant	NOUN	NN	Number=Sing	7	compound	7:compound	Entity=(abstract-75)
7	defenses	defense	NOUN	NNS	Number=Plur	4	obj	4:obj	Entity=abstract-32)
8	,	,	PUNCT	,	_	4	punct	4:punct	_
9	increasing	increase	VERB	VBG	VerbForm=Ger	20	csubj	20:csubj	Discourse=elaboration:43->42
10	the	the	DET	DT	Definite=Def|PronType=Art	11	det	11:det	Entity=(abstract-76
11	expression	expression	NOUN	NN	Number=Sing	9	obj	9:obj	Entity=abstract-76)
12	or	or	CCONJ	CC	_	13	cc	13:cc	_
13	activity	activity	NOUN	NN	Number=Sing	11	conj	9:obj|11:conj:or	Entity=(abstract-77
14	of	of	ADP	IN	_	16	case	16:case	_
15	antioxidant	antioxidant	ADJ	JJ	Degree=Pos	16	amod	16:amod	Entity=(substance-78
16	enzymes	enzyme	NOUN	NNS	Number=Plur	11	nmod	11:nmod:of	Entity=abstract-77)substance-78)
17	could	could	AUX	MD	VerbForm=Fin	20	aux	20:aux	_
18	be	be	AUX	VB	VerbForm=Inf	20	cop	20:cop	_
19	a	a	DET	DT	Definite=Ind|PronType=Art	20	det	20:det	Entity=(abstract-79
20	mechanism	mechanism	NOUN	NN	Number=Sing	0	root	0:root	_
21	of	of	ADP	IN	_	23	case	23:case	_
22	cardiac	cardiac	ADJ	JJ	Degree=Pos	23	amod	23:amod	Entity=(abstract-44
23	protection	protection	NOUN	NN	Number=Sing	20	nmod	20:nmod:of	_
24	under	under	ADP	IN	_	27	case	27:case	_
25	high	high	ADJ	JJ	Degree=Pos	26	amod	26:amod	Entity=(abstract-80(abstract-81
26	risk	risk	NOUN	NN	Number=Sing	27	compound	27:compound	Entity=abstract-81)
27	situations	situation	NOUN	NNS	Number=Plur	23	nmod	23:nmod:under	_
28	such	such	ADJ	JJ	Degree=Pos	30	case	30:case	_
29	as	as	ADP	IN	_	28	fixed	28:fixed	_
30	T2D	T2D	NOUN	NN	Number=Sing	27	nmod	27:nmod:such_as	Entity=abstract-79)abstract-44)abstract-80)(abstract-20)
31	.	.	PUNCT	.	_	20	punct	20:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_empagliflozin-16
# text = Oxidative stress occurs when the production of pro-oxidant species overcomes the intrinsic antioxidant defense system of the cell , thus triggering damage to lipids , proteins and DNA , and eventually compromising cellular and tissue function .
1	Oxidative	oxidative	NOUN	NN	Number=Sing	2	compound	2:compound	Discourse=joint:44->42|Entity=(abstract-17(abstract-72)
2	stress	stress	NOUN	NN	Number=Sing	3	nsubj	3:nsubj	Entity=abstract-17)
3	occurs	occur	VERB	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	0	root	0:root	_
4	when	when	SCONJ	WRB	PronType=Int	10	mark	10:mark	Discourse=circumstance:45->44
5	the	the	DET	DT	Definite=Def|PronType=Art	6	det	6:det	Entity=(abstract-27
6	production	production	NOUN	NN	Number=Sing	10	nsubj	10:nsubj	_
7	of	of	ADP	IN	_	9	case	9:case	_
8	pro-oxidant	pro-oxidant	ADJ	JJ	Degree=Pos	9	amod	9:amod	Entity=(plant-82
9	species	species	NOUN	NNS	Number=Plur	6	nmod	6:nmod:of	Entity=abstract-27)plant-82)
10	overcomes	overcome	VERB	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	3	advcl	3:advcl:when	_
11	the	the	DET	DT	Definite=Def|PronType=Art	15	det	15:det	Entity=(abstract-56
12	intrinsic	intrinsic	ADJ	JJ	Degree=Pos	15	amod	15:amod	_
13	antioxidant	antioxidant	ADJ	JJ	Degree=Pos	14	amod	14:amod	Entity=(abstract-83
14	defense	defense	NOUN	NN	Number=Sing	15	compound	15:compound	Entity=abstract-83)
15	system	system	NOUN	NN	Number=Sing	10	obj	10:obj	_
16	of	of	ADP	IN	_	18	case	18:case	_
17	the	the	DET	DT	Definite=Def|PronType=Art	18	det	18:det	Entity=(place-84
18	cell	cell	NOUN	NN	Number=Sing	15	nmod	15:nmod:of	Entity=abstract-56)place-84)
19	,	,	PUNCT	,	_	21	punct	21:punct	_
20	thus	thus	ADV	RB	_	21	advmod	21:advmod	Discourse=result:46->45
21	triggering	trigger	VERB	VBG	VerbForm=Ger	10	advcl	10:advcl	_
22	damage	damage	NOUN	NN	Number=Sing	21	obj	21:obj	Entity=(abstract-85
23	to	to	ADP	IN	_	24	case	24:case	_
24	lipids	lipid	NOUN	NNS	Number=Plur	22	nmod	22:nmod:to	Entity=(substance-86)
25	,	,	PUNCT	,	_	26	punct	26:punct	_
26	proteins	protein	NOUN	NNS	Number=Plur	24	conj	22:nmod:to|24:conj:and	Entity=(substance-87)
27	and	and	CCONJ	CC	_	28	cc	28:cc	_
28	DNA	DNA	NOUN	NN	Abbr=Yes|Number=Sing	24	conj	22:nmod:to|24:conj:and	Entity=abstract-85)(substance-88)
29	,	,	PUNCT	,	_	32	punct	32:punct	_
30	and	and	CCONJ	CC	_	32	cc	32:cc	Discourse=joint:47->46
31	eventually	eventually	ADV	RB	Degree=Pos	32	advmod	32:advmod	_
32	compromising	compromise	VERB	VBG	VerbForm=Ger	21	conj	10:advcl|21:conj:and	_
33	cellular	cellular	ADJ	JJ	Degree=Pos	36	amod	36:amod	Entity=(abstract-89
34	and	and	CCONJ	CC	_	35	cc	35:cc	_
35	tissue	tissue	NOUN	NN	Number=Sing	33	conj	33:conj:and|36:compound	_
36	function	function	NOUN	NN	Number=Sing	32	obj	32:obj	Entity=abstract-89)
37	.	.	PUNCT	.	_	3	punct	3:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_empagliflozin-17
# text = Exploring the role of SGLT2 inhibition in the prevention or reduction of oxidative stress conditions has been the subject of several studies over the last decade .
1	Exploring	explore	VERB	VBG	VerbForm=Ger	19	csubj	19:csubj	Discourse=joint:48->44
2	the	the	DET	DT	Definite=Def|PronType=Art	3	det	3:det	Entity=(abstract-90
3	role	role	NOUN	NN	Number=Sing	1	obj	1:obj	_
4	of	of	ADP	IN	_	6	case	6:case	_
5	SGLT2	SGLT2	NOUN	NN	Number=Sing	6	compound	6:compound	Entity=(abstract-91(substance-92)
6	inhibition	inhibition	NOUN	NN	Number=Sing	3	nmod	3:nmod:of	Entity=abstract-91)
7	in	in	ADP	IN	_	9	case	9:case	_
8	the	the	DET	DT	Definite=Def|PronType=Art	9	det	9:det	Entity=(abstract-93
9	prevention	prevention	NOUN	NN	Number=Sing	3	nmod	3:nmod:in	Entity=abstract-93)
10	or	or	CCONJ	CC	_	11	cc	11:cc	_
11	reduction	reduction	NOUN	NN	Number=Sing	9	conj	3:nmod:in|9:conj:or	Entity=(abstract-94
12	of	of	ADP	IN	_	15	case	15:case	_
13	oxidative	oxidative	ADJ	JJ	Degree=Pos	14	amod	14:amod	Entity=(abstract-95(abstract-17
14	stress	stress	NOUN	NN	Number=Sing	15	compound	15:compound	Entity=abstract-17)
15	conditions	condition	NOUN	NNS	Number=Plur	9	nmod	9:nmod:of	Entity=abstract-90)abstract-94)abstract-95)
16	has	have	AUX	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	19	aux	19:aux	_
17	been	be	AUX	VBN	Tense=Past|VerbForm=Part	19	cop	19:cop	_
18	the	the	DET	DT	Definite=Def|PronType=Art	19	det	19:det	Entity=(object-96
19	subject	subject	NOUN	NN	Number=Sing	0	root	0:root	_
20	of	of	ADP	IN	_	22	case	22:case	_
21	several	several	ADJ	JJ	Degree=Pos	22	amod	22:amod	Entity=(abstract-43
22	studies	study	NOUN	NNS	Number=Plur	19	nmod	19:nmod:of	Entity=abstract-43)
23	over	over	ADP	IN	_	26	case	26:case	_
24	the	the	DET	DT	Definite=Def|PronType=Art	26	det	26:det	Entity=(time-97
25	last	last	ADJ	JJ	Degree=Pos	26	amod	26:amod	_
26	decade	decade	NOUN	NN	Number=Sing	19	nmod	19:nmod:over	Entity=object-96)time-97)
27	.	.	PUNCT	.	_	19	punct	19:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_empagliflozin-18
# text = However , to date , most of the studies evaluating the effect of iSGLT2 on oxidative stress have been performed in animal models .
1	However	however	ADV	RB	_	20	advmod	20:advmod	Discourse=joint:49->48
2	,	,	PUNCT	,	_	1	punct	1:punct	_
3	to	to	ADP	IN	_	4	case	4:case	_
4	date	date	NOUN	NN	Number=Sing	20	obl	20:obl:to	Entity=(time-98)
5	,	,	PUNCT	,	_	4	punct	4:punct	_
6	most	most	ADJ	JJS	Degree=Sup	20	nsubj:pass	20:nsubj:pass	Entity=(abstract-43
7	of	of	ADP	IN	_	9	case	9:case	_
8	the	the	DET	DT	Definite=Def|PronType=Art	9	det	9:det	_
9	studies	study	NOUN	NNS	Number=Plur	6	obl	6:obl:of	_
10	evaluating	evaluate	VERB	VBG	VerbForm=Ger	9	acl	9:acl	Discourse=elaboration:50->49
11	the	the	DET	DT	Definite=Def|PronType=Art	12	det	12:det	Entity=(abstract-35
12	effect	effect	NOUN	NN	Number=Sing	10	obj	10:obj	_
13	of	of	ADP	IN	_	14	case	14:case	_
14	iSGLT2	iSGLT2	PROPN	NNP	Number=Sing	12	nmod	12:nmod:of	Entity=(abstract-31)
15	on	on	ADP	IN	_	17	case	17:case	_
16	oxidative	oxidative	NOUN	NN	Number=Sing	17	compound	17:compound	Entity=(abstract-17(abstract-72)
17	stress	stress	NOUN	NN	Number=Sing	12	nmod	12:nmod:on	Entity=abstract-43)abstract-35)abstract-17)
18	have	have	AUX	VBP	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	20	aux	20:aux	_
19	been	be	AUX	VBN	Tense=Past|VerbForm=Part	20	aux:pass	20:aux:pass	_
20	performed	perform	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
21	in	in	ADP	IN	_	23	case	23:case	_
22	animal	animal	NOUN	NN	Number=Sing	23	compound	23:compound	Entity=(abstract-99(animal-100)
23	models	model	NOUN	NNS	Number=Plur	20	obl	20:obl:in	Entity=abstract-99)
24	.	.	PUNCT	.	_	20	punct	20:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_empagliflozin-19
# text = Our data demonstrate that T2D patients receiving iSGLT2 treatment undergo a reduction in mitochondrial superoxide production in parallel to an increase in glutathione content , and markedly so after 24 weeks of treatment .
1	Our	our	PRON	PRP$	Number=Plur|Person=1|Poss=Yes|PronType=Prs	2	nmod:poss	2:nmod:poss	Discourse=attribution:51->52|Entity=(abstract-101(person-14)
2	data	datum	NOUN	NNS	Number=Plur	3	nsubj	3:nsubj	Entity=abstract-101)
3	demonstrate	demonstrate	VERB	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	0	root	0:root	_
4	that	that	SCONJ	IN	_	10	mark	10:mark	Discourse=joint:52->49
5	T2D	T2D	PROPN	NNP	Number=Sing	6	compound	6:compound	Entity=(person-29(abstract-20)
6	patients	patient	NOUN	NNS	Number=Plur	10	nsubj	10:nsubj	_
7	receiving	receive	VERB	VBG	VerbForm=Ger	6	acl	6:acl	Discourse=elaboration:53->52
8	iSGLT2	iSGLT2	PROPN	NNP	Number=Sing	9	compound	9:compound	Entity=(abstract-30(abstract-31)
9	treatment	treatment	NOUN	NN	Number=Sing	7	obj	7:obj	Entity=person-29)abstract-30)
10	undergo	undergo	VERB	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	3	ccomp	3:ccomp	Discourse=same_unit:54->53
11	a	a	DET	DT	Definite=Ind|PronType=Art	12	det	12:det	Entity=(abstract-94
12	reduction	reduction	NOUN	NN	Number=Sing	10	obj	10:obj	_
13	in	in	ADP	IN	_	16	case	16:case	_
14	mitochondrial	mitochondrial	ADJ	JJ	Degree=Pos	16	amod	16:amod	Entity=(abstract-27
15	superoxide	superoxide	NOUN	NN	Number=Sing	16	compound	16:compound	Entity=(substance-28)
16	production	production	NOUN	NN	Number=Sing	12	nmod	12:nmod:in	Entity=abstract-27)
17	in	in	ADP	IN	_	18	case	18:case	_
18	parallel	parallel	NOUN	NN	Number=Sing	10	obl	10:obl:in	_
19	to	to	ADP	IN	_	21	case	21:case	_
20	an	a	DET	DT	Definite=Ind|PronType=Art	21	det	21:det	Entity=(event-102
21	increase	increase	NOUN	NN	Number=Sing	12	nmod	12:nmod:to	_
22	in	in	ADP	IN	_	24	case	24:case	_
23	glutathione	glutathione	NOUN	NN	Number=Sing	24	compound	24:compound	Entity=(abstract-103(abstract-104)
24	content	content	NOUN	NN	Number=Sing	21	nmod	21:nmod:in	Entity=abstract-94)event-102)abstract-103)
25	,	,	PUNCT	,	_	28	punct	28:punct	_
26	and	and	CCONJ	CC	_	28	cc	28:cc	Discourse=joint:55->53
27	markedly	markedly	ADV	RB	Degree=Pos	28	advmod	28:advmod	_
28	so	so	ADV	RB	_	10	conj	3:ccomp|10:conj:and	_
29	after	after	ADP	IN	_	31	case	31:case	_
30	24	24	NUM	CD	NumForm=Digit|NumType=Card	31	nummod	31:nummod	Entity=(time-105
31	weeks	week	NOUN	NNS	Number=Plur	28	nmod	28:nmod:after	_
32	of	of	ADP	IN	_	33	case	33:case	_
33	treatment	treatment	NOUN	NN	Number=Sing	31	nmod	31:nmod:of	Entity=time-105)(abstract-30)
34	.	.	PUNCT	.	_	3	punct	3:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_empagliflozin-20
# text = This is accompanied by increased expression of the antioxidant enzymes GSR and CAT .
1	This	this	PRON	DT	Number=Sing|PronType=Dem	3	nsubj:pass	3:nsubj:pass	Discourse=joint:56->52|Entity=(abstract-103)
2	is	be	AUX	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	3	aux:pass	3:aux:pass	_
3	accompanied	accompany	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
4	by	by	ADP	IN	_	6	case	6:case	_
5	increased	increase	VERB	VBN	Tense=Past|VerbForm=Part	6	amod	6:amod	Entity=(abstract-76
6	expression	expression	NOUN	NN	Number=Sing	3	obl	3:obl:by	_
7	of	of	ADP	IN	_	10	case	10:case	_
8	the	the	DET	DT	Definite=Def|PronType=Art	10	det	10:det	Entity=(abstract-106(substance-78
9	antioxidant	antioxidant	NOUN	NN	Number=Sing	10	compound	10:compound	Entity=(abstract-75)
10	enzymes	enzyme	NOUN	NNS	Number=Plur	6	nmod	6:nmod:of	Entity=substance-78)
11	GSR	GSR	PROPN	NNP	Number=Sing	10	appos	10:appos	Entity=abstract-106)
12	and	and	CCONJ	CC	_	13	cc	13:cc	_
13	CAT	CAT	PROPN	NNP	Number=Sing	11	conj	10:appos|11:conj:and	Entity=abstract-76)(object-107)
14	.	.	PUNCT	.	_	3	punct	3:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_empagliflozin-21
# text = However , no changes in plasma protein carbonyl content were observed with empagliflozin treatment at these time-points .
1	However	however	ADV	RB	_	11	advmod	11:advmod	Discourse=elaboration:57->56
2	,	,	PUNCT	,	_	1	punct	1:punct	_
3	no	no	DET	DT	Polarity=Neg	4	det	4:det	Entity=(abstract-37
4	changes	change	NOUN	NNS	Number=Plur	11	nsubj:pass	11:nsubj:pass	_
5	in	in	ADP	IN	_	9	case	9:case	_
6	plasma	plasma	NOUN	NN	Number=Sing	9	compound	9:compound	Entity=(abstract-103(abstract-12)
7	protein	protein	NOUN	NN	Number=Sing	9	compound	9:compound	Entity=(substance-108)
8	carbonyl	carbonyl	NOUN	NN	Number=Sing	9	compound	9:compound	Entity=(substance-109)
9	content	content	NOUN	NN	Number=Sing	4	nmod	4:nmod:in	Entity=abstract-37)abstract-103)
10	were	be	AUX	VBD	Mood=Ind|Number=Plur|Person=3|Tense=Past|VerbForm=Fin	11	aux:pass	11:aux:pass	_
11	observed	observe	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
12	with	with	ADP	IN	_	14	case	14:case	_
13	empagliflozin	empagliflozin	NOUN	NN	Number=Sing	14	compound	14:compound	Entity=(abstract-30(substance-16)
14	treatment	treatment	NOUN	NN	Number=Sing	11	obl	11:obl:with	Entity=abstract-30)
15	at	at	ADP	IN	_	17	case	17:case	_
16	these	this	DET	DT	Number=Plur|PronType=Dem	17	det	17:det	Entity=(time-110
17	time-points	time-point	NOUN	NNS	Number=Plur	11	obl	11:obl:at	Entity=time-110)
18	.	.	PUNCT	.	_	11	punct	11:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_empagliflozin-22
# text = Whether this could be due to the small sample size or would require long-term empagliflozin treatment needs to be addressed in future research .
1	Whether	whether	SCONJ	IN	_	5	mark	5:mark	Discourse=joint:58->56
2	this	this	PRON	DT	Number=Sing|PronType=Dem	5	nsubj	5:nsubj	Entity=(abstract-30)
3	could	could	AUX	MD	VerbForm=Fin	5	aux	5:aux	_
4	be	be	AUX	VB	VerbForm=Inf	5	cop	5:cop	_
5	due	due	ADJ	JJ	Degree=Pos	17	advcl	17:advcl:whether	_
6	to	to	ADP	IN	_	10	case	10:case	_
7	the	the	DET	DT	Definite=Def|PronType=Art	10	det	10:det	Entity=(abstract-111
8	small	small	ADJ	JJ	Degree=Pos	10	amod	10:amod	_
9	sample	sample	NOUN	NN	Number=Sing	10	compound	10:compound	Entity=(object-112)
10	size	size	NOUN	NN	Number=Sing	5	obl	5:obl:to	Entity=abstract-111)
11	or	or	CCONJ	CC	_	13	cc	13:cc	Discourse=contrast:59->58
12	would	would	AUX	MD	VerbForm=Fin	13	aux	13:aux	_
13	require	require	VERB	VB	Mood=Imp|Person=2|VerbForm=Fin	5	conj	5:conj:or|17:advcl:whether	_
14	long-term	long-term	ADJ	JJ	Degree=Pos	16	amod	16:amod	Entity=(abstract-30
15	empagliflozin	empagliflozin	NOUN	NN	Number=Sing	16	compound	16:compound	Entity=(substance-16)
16	treatment	treatment	NOUN	NN	Number=Sing	13	obj	13:obj	Entity=abstract-30)
17	needs	need	VERB	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	0	root	0:root	_
18	to	to	PART	TO	_	20	mark	20:mark	_
19	be	be	AUX	VB	VerbForm=Inf	20	aux:pass	20:aux:pass	_
20	addressed	address	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	17	xcomp	17:xcomp	_
21	in	in	ADP	IN	_	23	case	23:case	_
22	future	future	ADJ	JJ	Degree=Pos	23	amod	23:amod	Entity=(abstract-113
23	research	research	NOUN	NN	Number=Sing	20	obl	20:obl:in	Entity=abstract-113)
24	.	.	PUNCT	.	_	17	punct	17:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_empagliflozin-23
# text = Our findings are in accordance with previous studies in rat models of T2D , in which increased antioxidant enzyme content and activity in renal tissues has been reported .
1	Our	our	PRON	PRP$	Number=Plur|Person=1|Poss=Yes|PronType=Prs	2	nmod:poss	2:nmod:poss	Discourse=joint:60->58|Entity=(abstract-114(person-14)
2	findings	finding	NOUN	NNS	Number=Plur	5	nsubj	5:nsubj	Entity=abstract-114)
3	are	be	AUX	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	5	cop	5:cop	_
4	in	in	ADP	IN	_	5	case	5:case	_
5	accordance	accordance	NOUN	NN	Number=Sing	0	root	0:root	_
6	with	with	ADP	IN	_	8	case	8:case	_
7	previous	previous	ADJ	JJ	Degree=Pos	8	amod	8:amod	Entity=(abstract-43
8	studies	study	NOUN	NNS	Number=Plur	5	nmod	5:nmod:with|28:obl:in	_
9	in	in	ADP	IN	_	11	case	11:case	_
10	rat	rat	NOUN	NN	Number=Sing	11	compound	11:compound	Entity=(abstract-99(animal-115)
11	models	model	NOUN	NNS	Number=Plur	8	nmod	8:nmod:in	_
12	of	of	ADP	IN	_	13	case	13:case	_
13	T2D	T2D	NOUN	NN	Number=Sing	11	nmod	11:nmod:of	Entity=abstract-99)(abstract-20)
14	,	,	PUNCT	,	_	28	punct	28:punct	_
15	in	in	ADP	IN	_	16	case	16:case	Discourse=elaboration:61->60
16	which	which	PRON	WDT	PronType=Rel	28	obl	8:ref	_
17	increased	increase	VERB	VBN	Tense=Past|VerbForm=Part	20	amod	20:amod	Entity=(abstract-103
18	antioxidant	antioxidant	ADJ	JJ	Degree=Pos	20	amod	20:amod	_
19	enzyme	enzyme	NOUN	NN	Number=Sing	20	compound	20:compound	Entity=(substance-116)
20	content	content	NOUN	NN	Number=Sing	28	nsubj:pass	28:nsubj:pass	Entity=abstract-103)
21	and	and	CCONJ	CC	_	22	cc	22:cc	_
22	activity	activity	NOUN	NN	Number=Sing	20	conj	20:conj:and|28:nsubj:pass	Entity=(abstract-77
23	in	in	ADP	IN	_	25	case	25:case	_
24	renal	renal	ADJ	JJ	Degree=Pos	25	amod	25:amod	Entity=(object-117
25	tissues	tissue	NOUN	NNS	Number=Plur	20	nmod	20:nmod:in	Entity=abstract-77)object-117)
26	has	have	AUX	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	28	aux	28:aux	_
27	been	be	AUX	VBN	Tense=Past|VerbForm=Part	28	aux:pass	28:aux:pass	_
28	reported	report	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	8	acl:relcl	8:acl:relcl	Entity=abstract-43)
29	.	.	PUNCT	.	_	5	punct	5:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_empagliflozin-24
# text = Furthermore , iSGLT2 treatment in diabetic mice has been shown to induce antioxidant gene expression ( manganese-dependent superoxide dismutase and CAT ) in adipose tissue and muscle .
1	Furthermore	furthermore	ADV	RB	Degree=Pos	10	advmod	10:advmod	Discourse=joint:62->60
2	,	,	PUNCT	,	_	1	punct	1:punct	_
3	iSGLT2	iSGLT2	PROPN	NNP	Number=Sing	4	compound	4:compound	Entity=(abstract-30(abstract-31)
4	treatment	treatment	NOUN	NN	Number=Sing	10	nsubj:pass	10:nsubj:pass|12:nsubj:xsubj	_
5	in	in	ADP	IN	_	7	case	7:case	_
6	diabetic	diabetic	ADJ	JJ	Degree=Pos	7	amod	7:amod	Entity=(animal-118
7	mice	mouse	NOUN	NNS	Number=Plur	4	nmod	4:nmod:in	Entity=abstract-30)animal-118)
8	has	have	AUX	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	10	aux	10:aux	_
9	been	be	AUX	VBN	Tense=Past|VerbForm=Part	10	aux:pass	10:aux:pass	_
10	shown	show	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
11	to	to	PART	TO	_	12	mark	12:mark	_
12	induce	induce	VERB	VB	VerbForm=Inf	10	xcomp	10:xcomp	_
13	antioxidant	antioxidant	NOUN	NN	Number=Sing	15	compound	15:compound	Entity=(abstract-76(person-119)
14	gene	gene	NOUN	NN	Number=Sing	15	compound	15:compound	Entity=(abstract-120)
15	expression	expression	NOUN	NN	Number=Sing	12	obj	12:obj	Entity=abstract-76)
16	(	(	PUNCT	-LRB-	_	19	punct	19:punct	Discourse=elaboration:63->62
17	manganese-dependent	manganese-dependent	ADJ	JJ	Degree=Pos	19	amod	19:amod	Entity=(abstract-76(substance-121
18	superoxide	superoxide	NOUN	NN	Number=Sing	19	compound	19:compound	Entity=(substance-28)
19	dismutase	dismutase	NOUN	NN	Number=Sing	15	appos	15:appos	Entity=substance-121)
20	and	and	CCONJ	CC	_	21	cc	21:cc	_
21	CAT	CAT	NOUN	NN	Number=Sing	19	conj	15:appos|19:conj:and	Entity=abstract-76)(object-107)
22	)	)	PUNCT	-RRB-	_	19	punct	19:punct	_
23	in	in	ADP	IN	_	25	case	25:case	Discourse=same_unit:64->62
24	adipose	adipose	NOUN	NN	Number=Sing	25	compound	25:compound	Entity=(object-74(abstract-122)
25	tissue	tissue	NOUN	NN	Number=Sing	12	obl	12:obl:in	Entity=object-74)
26	and	and	CCONJ	CC	_	27	cc	27:cc	_
27	muscle	muscle	NOUN	NN	Number=Sing	25	conj	12:obl:in|25:conj:and	Entity=(object-123)
28	.	.	PUNCT	.	_	10	punct	10:punct	_

